Publication
Neuropeptide kyotorphin (tyrosyl-arginine) has decreased levels in the cerebro-spinal fluid of Alzheimer’s disease patients: potential diagnostic and pharmacological implications
| dc.contributor.author | Santos, Sara Matos | |
| dc.contributor.author | Garcia-Nimo, Laura | |
| dc.contributor.author | Sá Santos, Sónia | |
| dc.contributor.author | Tavares, Isaura | |
| dc.contributor.author | Cocho, José A. | |
| dc.contributor.author | Castanho, Miguel A. R. B. | |
| dc.date.accessioned | 2014-03-10T14:11:36Z | |
| dc.date.available | 2014-03-10T14:11:36Z | |
| dc.date.issued | 2013 | |
| dc.description.abstract | In Alzheimer’s disease (AD), besides the characteristic deterioration of memory, studies also point to a higher pain tolerance in spite of sensibility preservation. A change in the normal tau protein phosphorylation is also characteristic of AD, which contributes to the pathogenesis of the disease and is useful in early diagnosis. Kyotorphin (KTP) is an endoge-nous analgesic dipeptide (Tyr-Arg) for which there is evidence of eventual neuroprotective and neuromodulatory properties. The objective of this work was to study the possible cor-relation between KTP and phosphorylated tau protein (p-tau) levels in cerebro-spinal fluid (CSF) samples of AD patients. CSF samples were collected from 25 AD patients and 13 age-matched controls (N), where p-tau and KTP levels were measured.We found a statis-tically significant difference between p-tau/KTP values in AD and N groups with an inverse correlation between p-tau and KTP values in AD samples. These results suggest that in the future KTP may be a candidate biomarker for neurodegeneration and may be a lead compound to be used pharmacologically for neuroprotection. | eng |
| dc.description.sponsorship | Fundação para a Ciência e Tecnologia (FCT, Portugal) is acknowledged for fellowship SFRH/BPD/79542/2011 to Sónia Sá Santos and Grant PTDC/QUI-BIQ/112929/2009. MarieCurie International Research Staff Exchange Scheme (IRSES) is also acknowledged forfunding (FP7-PEOPLE-2009-IRSES, project MEMPEPACROSS). | eng |
| dc.identifier.citation | Frontiers in Aging Neuroscience October 2013, Volume 5, Article 68 | eng |
| dc.identifier.issn | 1663-4365 | |
| dc.identifier.uri | http://dx.doi.org/10.3389/fnagi.2013.00068 | |
| dc.identifier.uri | http://hdl.handle.net/10451/10715 | |
| dc.language.iso | eng | por |
| dc.peerreviewed | yes | por |
| dc.publisher | Frontiers | por |
| dc.relation.publisherversion | This Document is Protected by copyright and was first published by Frontiers. All rights reserved. it is reproduced with permission. | eng |
| dc.subject | Kyotorphin | eng |
| dc.subject | Pain | eng |
| dc.subject | Alzheimer | eng |
| dc.subject | Drug | eng |
| dc.subject | Cerebro-spinal fluid | eng |
| dc.subject | Neuroprotection | eng |
| dc.title | Neuropeptide kyotorphin (tyrosyl-arginine) has decreased levels in the cerebro-spinal fluid of Alzheimer’s disease patients: potential diagnostic and pharmacological implications | eng |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.awardURI | info:eu-repo/grantAgreement/EC/FP7/247513 | |
| oaire.citation.startPage | 68 | por |
| oaire.citation.title | Frontiers in Aging Neuroscience | eng |
| oaire.citation.volume | 5 | por |
| oaire.fundingStream | FP7 | |
| project.funder.identifier | http://doi.org/10.13039/501100008530 | |
| project.funder.name | European Commission | |
| rcaap.rights | openAccess | por |
| rcaap.type | article | por |
| relation.isProjectOfPublication | 9a14f3fc-9671-4460-8a00-79594f5854e0 | |
| relation.isProjectOfPublication.latestForDiscovery | 9a14f3fc-9671-4460-8a00-79594f5854e0 |